Results 141 to 150 of about 13,799 (205)
From Ototoxicity to Otoprotection: Mechanism and Protective Strategies in Cisplatin Therapy. [PDF]
Pharmaceuticals (Basel)Iațentiuc A +11 more
europepmc +1 more source
Hearing Characteristics of Adults before Exposure to Potentially Ototoxic Chemotherapy. [PDF]
Int Arch OtorhinolaryngolPeruch CV +5 more
europepmc +1 more source
Comedication that increase the risk of cisplatin-induced hearing loss in pediatric cancer patients: a narrative literature review and meta-analysis. [PDF]
Front Oncolde Jager KE +5 more
europepmc +1 more source
Clinical and Social Determinants of Treatment Adherence in Cancer Patients: The Contributory Role of Hearing Loss. [PDF]
Laryngoscope Investig OtolaryngolKılıçtaş B +8 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Annals of Otology, Rhinology & Laryngology, 2021
Objectives: Teprotumumab, a novel monoclonal antibody, targets the insulin-like growth factor 1 (IGF-1) receptor. IGF-1 receptors, found in muscle and fat adjacent to the eye and implicated in Graves Ophthalmopathy, are also in the cochlea.
Julie Highland +3 more
openaire +2 more sources
Objectives: Teprotumumab, a novel monoclonal antibody, targets the insulin-like growth factor 1 (IGF-1) receptor. IGF-1 receptors, found in muscle and fat adjacent to the eye and implicated in Graves Ophthalmopathy, are also in the cochlea.
Julie Highland +3 more
openaire +2 more sources
Cancer Chemotherapy and Pharmacology, 1990
For assessment of the ototoxic potential of carboplatin [cis-diammine-1,1-cyclobutane dicarboxylate platinum(II); CBDCA], pure-tone audiograms were evaluated in 27 patients receiving a total of 119 doses of carboplatin in the range of 300-400 mg/m2.
I C, Kennedy +3 more
openaire +2 more sources
For assessment of the ototoxic potential of carboplatin [cis-diammine-1,1-cyclobutane dicarboxylate platinum(II); CBDCA], pure-tone audiograms were evaluated in 27 patients receiving a total of 119 doses of carboplatin in the range of 300-400 mg/m2.
I C, Kennedy +3 more
openaire +2 more sources
Annals of Otology, Rhinology & Laryngology, 1978
A case of oral neomycin ototoxicity is presented, followed by a summary of known cases in the English literature. While it is known that neomycin is concentrated in the inner ear fluids, at the present time the biochemical basis of its ototoxic effect has not been definitively elucidated.
K M, Ward, F J, Rounthwaite
openaire +2 more sources
A case of oral neomycin ototoxicity is presented, followed by a summary of known cases in the English literature. While it is known that neomycin is concentrated in the inner ear fluids, at the present time the biochemical basis of its ototoxic effect has not been definitively elucidated.
K M, Ward, F J, Rounthwaite
openaire +2 more sources
International Journal of Andrology, 1987
Ototoxicity is one of the unwanted side effects of cisplatin treatment. The first sign of hearing loss usually appears 3–4 days after the drug administration and occurs primarily in the higher frequencies. One hundred and eighty‐six women treated with a moderate dose of cisplatin (50 mg/m2every 4 weeks) for gynaecological cancer were studied.
G, Laurell +3 more
openaire +2 more sources
Ototoxicity is one of the unwanted side effects of cisplatin treatment. The first sign of hearing loss usually appears 3–4 days after the drug administration and occurs primarily in the higher frequencies. One hundred and eighty‐six women treated with a moderate dose of cisplatin (50 mg/m2every 4 weeks) for gynaecological cancer were studied.
G, Laurell +3 more
openaire +2 more sources